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Abstract

Ariful Islam
MEDICATIONS DEVELOPMENT FOR DRUG ADDICTION AND OTHER
NEUROPSYCHIATRIC DISORDERS
2018-2019
Thomas M. Keck, Ph.D.
Master of Science in Pharmaceutical Science

Drug addiction and abuse especially opiate and psychostimulant abuse is a national and
global crisis. IBNtxA (3-iodobenzoyl naltrexamine) is a novel μ opioid receptor (MOR)
agonist, a naloxone derivative, structurally related to the classical MOR antagonist
naltrexone. Recent studies suggest IBNtxA preferentially signals through truncated MOR
splice variants, producing a unique pharmacological profile resulting in potent analgesia
with reduced side effects. It has been found that M. vaccae has immunoregulatory effects
that can prevent stress-induced exaggeration of neuroinflammation in the brain. The
purpose of our pilot study is to develop medication for addiction and neuropsychiatric
disorders. According to our purpose, we evaluated a range of IBNtxA doses to more fully
assess its abuse liability and antiaddiction properties and the preimmunization effect of
heat-killed M. vaccae on cocaine addiction. IBNtxA represents an intriguing lead
compound for preclinical drug development specifically targeting MOR splice variants,
potentially creating effective analgesics with reduced side effects. Furthermore, IBNtxA
could have use as an adjunct therapy in agonist replacement strategies (e.g., methadone).
M. vaccae might be helpful for cocaine relapse. Current collaborative efforts are aimed to
find the total signaling pathways of IBNtxA and the effect of M. vaccae on cocaine selfadministration, cocaine induced neuroinflammations and to keep finding medicine for
neurological diseases.
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Chapter 1
Introduction
Background
A brief history of opiate drugs. Opiates are a very old class of analgesic drugs
derived directly from the opium poppy. (Manglik et al., 2012)The term opiate refers
specifically to [list compounds]. Since opium has a long history, it is pretty difficult to
claim when it was first used (or abused), but scholars agree that the Sumerians in
Mesopotamia, present-day Iraq, cultivated and isolated opium from the opium poppy
(Papaver somniferu) around 3400 B.C. They named the plant “hul gil,” meaning “the plant
of joy.”(Brownstein, 1993; Rosenblum, Marsch, Joseph, & Portenoy, 2008) In 1806, the
German chemist Friedrich Wilhelm Adam Sertürner isolated morphine from opium and
named it “morphine” after the god of dreams, Morpheus. (Brownstein, 1993; Duarte, 2005)
In the 1850s, Alexander Wood reported that he had injected morphine into his wife as an
experiment, using his invented syringe with hollow needle, and his wife died from
respiratory depression. (Jonkman et al., 2018)
In the United States, opiates like morphine have been used since the American Civil
War as potent analgesics. Opiate use outside of medical treatment led to opiate abuse and
addiction. The Harrison Narcotics Tax Act was passed in 1914 to curb the addiction and
abuse of some highly addictive opiates and cocaine, which means possession without a
prescription of these drugs inside the United States is a criminal offense. (Terry, 1915)
The term opioid means opiate-like—a combination of the word opium and the
suffix –oid, meaning “like” or “resembling”—originated in 1950, and was first proposed
by Dr. George H. Acheson. (Wikler, Martin, Pescor, & Eades, 1963) Opioid drugs have
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structural similarities with morphine but are either synthetic or semisynthetic. (Martin,
1983) The endogenous (i.e., naturally occurring) opioid peptides, endorphins, were first
discovered in 1974 by two independent group of investigators—John Hughes and Hans
Kosterlitz of Scotland, and Rabi Simantov and Solomon H. Snyder of the United States.
(McLaughlin & Zagon, 2013)
Opioid drug classifications. Opioid drugs encompass a broad spectrum of activity.
According to their synthetic process, clinical opioids can be classified into three groups:
1. Naturally obtained, extracted directly from poppy seeds, such as morphine,
papaverine, and codeine;
2. Semi-synthetic compounds, which feature modifications of natural compounds,
including morphine esters such as heroin, oxycodone, and oxymorphone;
3. Fully synthetic compounds, such as pethidine, fentanyl, and tramadol. (Jamison
& Mao, 2015; Pathan & Williams, 2012)
Opioids can also be classified based upon their binding affinity and effects on the four
major opioid receptors:
1. The δ-opioid receptor (DOR);
2. The κ-opioid receptor (KOR);
3. The μ-opioid receptor (MOR);
4. The nociception/orphanin opioid receptor (NOR).
Finally, opioids can be classified based on their signaling properties:
1. Full agonists (e.g., morphine, etorphine, methadone, meperidine, codeine,
hydromorphone etc.), which will fully activate a given opioid receptor;

2

2. Partial agonists (e.g., buprenorphine, pentazocine, nalbuphine), which will
partially activate a given opioid receptor;
3. Antagonists (e.g., naloxone, naltrexone insert other examples?), which will
block the activity of agonists or partial agonists. (Jamison & Mao, 2015;
Waldhoer, Bartlett, & Whistler, 2004)
Other than clinical opioids, the body itself also produces opioid peptides,
commonly known as endogenous opioids or endogenous ligands. These endogenous
opioids bind to opioid receptors and exert pharmacological actions. (Holden; Li et al.,
2012; Waldhoer et al., 2004) Though there are many identified endogenous opioid
peptides, they can be classified into three groups of ligands—enkephalins, endorphins, and
dynorphins—which generally signal through the three major receptors, DOR, MOR, and
KOR, respectively. (Li et al., 2012)
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Table 1
Common clinical and endogenous opioid ligands. (Egan, 2005; Endoh, Matsuura,
Tanaka, & Nagase, 1992; Gilman, 2011; Jamison & Mao, 2015; Maisonneuve, Archer, &
Glick, 1994; Pathan & Williams, 2012; Trescot, Datta, Lee, & Hansen, 2008)
Opioid Ligands

Mu Opioid
Receptor

Delta Opioid
Receptor

Kappa Opioid
Receptor

Nociceptin
Receptor

+++

+

Endogenous Ligands
β-endorphin

+++

+++

Enkephalins

++

+++

Dynorphin A&B

++

+

Nociceptin/orphanin
FQ

Morphine

+++
Clinical and Nonclinical Ligands
Agonists
+++

Codeine

+

+

Fentanyl

+++

+

Pethidine

+++

+

Methadone

+++

U50,488

+
+
+
+++

TAN-67 (SB205,607)

+++
Partial Agonists

Buprenorphine

+

Pentazocine

-

Naloxone
Naltrexone
Norbinaltorphimine

-----

-+

++

Antagonists
-

------

(+) sign indicates receptor selectivity of opioid agonists, more (+) sign means more selectivity, no (+) sign
indicates, no selectivity. (–) sign indicates receptor selectivity of opioid antagonists, more (-) sign indicates
more antagonist effect.
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Opioid receptors. Opioid ligands signal through opioid receptors, which are
members of the 7-transmembrane G protein-coupled receptor (GPCR) superfamily. Opioid
receptors are widely found in the central nervous system but also found in the peripheral
nervous system. (Stein, 2016; Waldhoer et al., 2004) Though these receptors belong to the
same class, their functions and cellular localizations are quite different. Most full agonists,
such as morphine, endomorphins, fentanyl, and pethidine, primarily show pharmacological
effects upon binding through MOR. (Stein, 2016; Trescot et al., 2008) It has three major
subtypes of MOR, μ1, μ2, and μ3, located (Figure 2) in the brain—primarily in the cortex,
thalamus, periaqueductal gray (PG) —and spinal cord substantia gelatinosa. MOR are also
heavily expressed in the intestinal tract. (Mao, 1999; Stein, Schäfer, & Machelska, 2003)
Individual MOR subtypes have different functions: μ1 is responsible for supraspinal
analgesia, and physical dependence; μ2 is responsible for respiratory depression, euphoria,
physical dependence, reduced gastrointestinal motility, and miosis; and μ3 may affect
vasodilation. (Mao, 1999; Stein et al., 2003)
Endogenous opioids, like endorphin and encephalin, have more receptor selectivity
for DOR over clinical opioids which are most available pontine nuclei, amygdala and
olfactory bulbs of CNS (Figure 2). It has two subtypes δ1 & δ2, though individual subtype’s
function is not so obvious but DOR responsible for analgesia, euphoria, physical
dependence, convulsant, and antidepressant effects. (Chung & Kieffer, 2013; Mao, 1999)
In the brain, KOR mostly presents in hypothalamus, periaqueductal gray, and claustrum;
in the spinal cord, KOR mostly presents in the substantia gelatinosa (Figure 2). KOR
activation produces spinal analgesia, sedation, miosis, dysphoria, neuroprotection, and
diuresis. KOR has three known subtypes, κ1, κ2, and κ3. (Lalanne, Ayranci, Kieffer, & Lutz,
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2014; Stein et al., 2003) NOR is densely expressed (Figure 2) in cortex, ventral forebrain,
hippocampus, hypothalamus, amygdala, and in the dorsal horn of spinal cord. (Donica,
Awwad, Thakker, & Standifer, 2013; Koob, Arends, & Le Moal, 2014) Activation of NOR,
produces some physiological pharmacological responses such as anxiety, food intake,
learning, locomotor etc. (Donica et al., 2013)
Mechanisms action of opioid agonists. Opioids bind to opioid receptors, producing
a series of intracellular changes resulting in pharmacological effects. First, GTP binding at
Gα subunit, guanosine triphosphate (GTP) exchanges to guanosine diphosphate (GDP) that
triggers α-GTP complex to dissociate away from the βγ complex (Figure 1). (McDonald
& Lambert, 2005; Pathan & Williams, 2012; Stein, 2016) Free α-GTP and βγ interact with
the target protein and inhibit adenylate cyclase, which decreases cyclic adenosine
monophosphate (cAMP) inside the cell (Figure 2).(McDonald & Lambert, 2005; Pathan &
Williams, 2012) MOR, DOR, and KOR signaling can also moderate Ca2+ channels (Figure
1) in both pre- and post-synapse reduces Ca2+ inside cell and impaired the neurons’
excitability. (Simons, 1988; Stein, 2016) These intercellular events cause hyperpolarization
as well as hinder neuronal firing in key nociceptive circuits and eventually reduces pain.
(McDonald & Lambert, 2005; Pathan & Williams, 2012; Simons, 1988; Stein, 2016)
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Figure 1. from McDonald and Lambert (2005) Mechanism of actions opioid
receptor ligands. Binding of an opioid agonist to a G protein-coupled opioid
receptor induces the Gα protein to exchange its bound GDP for GTP, which causes
Gα-GTP complex to dissociate away from the Gβγ complex, and all G proteins to
dissociate from the receptor. (Pathan & Williams, 2012) Free Gα-GTP and Gβγ
interact with target proteins. αi/o, the G protein associated with all opioid receptors,
inhibits adenylate cyclase, reducing synthesis of cAMP. Gα and Gβγ also have
complex interactions at various Ca2+ and K+ ion channels. In neurons, opioid
receptor activation typically results in the suppression of neuronal firing.
(McDonald & Lambert, 2005)
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Extensive use of opioid drugs.
Pain management. Over a hundred years, opioids have been used for treating both
chronic and acute pain which is not only the national health issue but also an important
global health issue. In the United States, more than 100 million people suffer from chronic
pain and among them, 5-8 million use opioid drugs for long-term treatment. (Jamison &
Mao, 2015; Kalso, Edwards, Moore, & McQuay, 2004) Opioid analgesics are very
effective in both cancer and non-cancer pain too. Several clinical studies showed that
intravenous infusion of opioid analgesic significantly reduces the neuropathic pain like
central pain, postherpetic neuralgia, mixed neuropathic pain. (Kalso et al., 2004) Numerous
studies had confirmed the significance of different doses of oral opioid analgesics on
neuropathic, musculoskeletal and other non-cancer pain. (Kalso et al., 2004) The
effectiveness of opioid drugs to manage cancer pain has already been confirmed by WHO.
Severe pain in cancer patients is very challenging to manage and almost 75% of them need
to be treated with opioids analgesics. (Thapa, Rastogi, & Ahuja, 2011) Among all opioid
drugs, morphine alone is sufficient for 85% of patients as single pharmacotherapy to treat
severe cancer pain. In other cases, combination therapy with other analgesics or antineoplastic drugs can be more effective. (Gilson, Ryan, Joranson, & Dahl, 2004)
Sometimes, switching from one opioid drug (which already has receptor-resistance) to
another opioid drug can be effective to get superior analgesic effect. (Thapa et al., 2011)
Though success rate of opioid drugs is higher in cancer pain management but there are
many barriers make it intricate. Unavailability of morphine, economic crises in developing
countries, and improper pain assessment are some of the obstacles for pain management.
(Thapa et al., 2011)
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Acute pulmonary edema. Morphine has been used for a long time to treat
pulmonary edema. Because of the failure of the left ventricle, the pulmonary circulation
also increases due to elevated hydrostatic pressure which causes extra fluids accumulation
into interstitium and alveoli of lungs. (Ellingsrud & Agewall, 2016) The aim of pulmonary
edema treatment is to reduce hydrostatic pressure through lowering preload and afterload
that can be achieved by vasodilation. (Mattu, Martinez, & Kelly, 2005) It has been thought,
though not obvious, morphine has both anxiolytic and vasodilatory properties which can
treat elevated pulmonary fluids by dilation.(Ellingsrud & Agewall, 2016) The European
heart failure guideline considered intravenous infusion of morphine 4-8 mg as treatment as
a treatment of pulmonary oedema guideline in 2012 through the American College of
Cardiology Foundation/American Heart Association did not consider morphine for treating
this disorder as a treatment guideline. (McMurray et al., 2012; Yancy et al., 2013)
However, the American Heart Failure Society suggests if morphine needs to be
administrated then should be incautious. ("Section 12: Evaluation and Management of
Patients with Acute Decompensated Heart Failure," 2010)
Diarrhea. Interestingly opioid drugs can treat irritable bowel syndrome with
diarrhea (IBS-D). Since there are limited options available for managing IBS-D, so finding
new treatment methods is crucial. Investigations on phase-3 clinical trials have found a
substantial effect of eluxadoline, a new oral mu opioid receptor agonist but it has mixed
opioids effect such as it also agonist KOR but antagonist of DOR, on IBS-D. (Lembo et
al., 2016)
Cough. Codeine has been used for decades as an antitussive opioid medication for
cough treatment. Numerous recent studies question the efficacy of codeine in treatment of
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cough. One study found that codeine did not have any significant effect on chronic
obstructive pulmonary disease (COPD) when compared to placebo even though it is a
standard antitussive agent. (Smith, Owen, Earis, & Woodcock, 2006) Codeine is
ineffective as a cough suppressant when it is generated due to upper respiratory disorder or
COPD, and it is not even effective for an acute cough in children. The U.S. Food and Drug
Administration (FDA) recently warned that any cough medication containing opioids
should not be used by patients less than 18 years old. However, still few studies claim,
codeine is effective for a chronic cough in adults. (McCrory et al., 2013)
Anesthesia. Opioid analgesics, especially narcotic opioids, have been widely using
as anesthetic agents for various terms of anesthetic medications practice. Opiates
analgesics are commonly used for major surgeries most specifically the surgical operation
of any patient who has the cardiovascular disorder. (Bovill, Sebel, & Stanley, 1984) The
principal reason for using opioids in patients with the cardiovascular disease during surgery
is the absence of cardiac depression. (Hug, 1992) Though opioid medications have some
side-effects in comparison with other anesthetic agents narcotic opioids even many cases
better. (Bovill et al., 1984; Hug, 1992) Proper knowledge of opioids pharmacology, doseresponse curves, and possible adverse effects can easily help to manage limitations of
narcotic opioid analgesics as anesthesia. (Hug, 1992)
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Adverse Effects of Opioids
Opioids analgesics accompany with inevitable adverse effects including respiratory
depression, sedation, euphoria, constipation, bradycardia etc. (Ballantyne & Mao 2003;
DeWire et al., 2013) Along with side effects, other adverse effects such as the addiction,
abuse, dependency, tolerance, hyperalgesia, and withdrawals symptoms make opioids
analgesic difficult to deal. (Fields & Margolis, 2015; Jamison & Mao, 2015; Volkow &
McLellan, 2016)
Tolerance. The term drug tolerance or medication tolerance can be simply defined
as when the body doesn’t response or show same pharmacological actions as it shows
initially with the same drug which means body requires higher dose over time to
demonstrate the desired therapeutic effect.(Savage et al., 2003) When drug tolerance
happens due to repeated opioids drugs exposure, the term could be renamed—opioid
tolerance.(Chang, Chen, & Mao, 2007) Scientists had been investigating the mechanism
behind this opioid analgesic tolerance and found multiple mechanisms but the most
convincing mechanisms are opioid receptor desensitization and internalization.(Pan, 2007)
Desensitized receptors decrease their functions by limiting cellular signaling and internalization

causes receptors reduction on the surface of the cell membrane and decreases receptors
availability for opioids ligand bindings. (Allouche, Noble, & Marie, 2014; Pan, 2007) This
signal transduction event takes place by two steps: the first step of desensitization occurs
through GPCR phosphorylation by G protein-coupled receptor kinases (GRKs) which
makes receptors ready for the second step—arresting bindings. (Pan, 2007) Once arresting
binding happens, it eventuates uncoupling G protein signaling from GPCRs through
blockage of G protein binding and other than only develops desensitization, it also
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promotes internalization. (Krupnick, Goodman, Keen, & Benovic, 1997) Switching to
another opioid analgesic or in combination with other analgesics as a part of pain therapy
helps to bypass opioid tolerance but probably finding complete new opioid agonist could
be more helpful.
Hyperalgesia. Opioid-induced hyperalgesia (OIH) is the state of a paradoxical
nociceptive sensitization response due to long-term opioids exposure. (Lee, Silverman,
Hansen, Patel, & Manchikanti, 2011) When it is supposed to reduce pain after getting
opioid analgesic therapy, but patients, instead, become more sensitive to painful stimuli in
many cases. Researchers interpreted that OIH is the consequence of opioid tolerance and
probably the first sign of hyperalgesia. (Chang et al., 2007) The molecular mechanism is
not yet well-characterized. Though a number of mechanisms have been assumed the
general surmise is the neoplastic modifications in both peripheral and central nervous may
lead to hyperalgesia. (Lee et al., 2011) The sign of OIH can be identified if there is a lack
of pharmacological efficacious responses during management of chronic pain with opioids
administrations. (Hayhurst & Durieux, 2016) This unwelcome OIH expression might be
managed by administration of low-dose ketamine, methadone, a combination of morphine
and dextromethorphan in 1:1 ratio, COX-2 inhibitors and also considering some other
treatment strategies. (Lee et al., 2011)
Addiction, abuse, and dependence. Addiction is a chronic and relapsing brain
disease where patients irresistibly seek drugs even though they know about the detrimental
consequences. Anything which can produce the feelings of euphemism can lead to
addiction and abuse, and this can be a drug, food, sex etc. (Savage et al., 2003) Most of the
opioid agonists can produce a reward, and direct to addiction, abuse and creates drug
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dependence. In general, dependence can be defined as the condition where the subject is
not able to cut down or quit specific substance because of long-term use, despite trying
harder and when it does happen with opioid drugs, called opioid dependence. (Jamison &
Mao, 2015; Rosenblum et al., 2008) Both addiction and dependence happen over time to
obtain a reward. Opioids addictive and dependent patients can do anything such as stealing
money or drug, begging, robbing or intimidating anyone to administrate drugs.
Opioid withdrawal. Drug withdrawal is a bunch of symptoms which become
obvious because of discontinuing or significant reduction all on a sudden of any substance
with or without medical values which have been administrating. Usually, the drugs which
can produce rewards may cause withdrawal disorders which might stay for a week or more
after an abrupt massive interfering of the last dose. Withdrawal symptoms can occur after
developing drug dependence. (Savage et al., 2003) Nausea, vomiting, muscle cramping,
depression, anxiety, opiate cravings, agitation etc. are common withdrawal symptoms.
(Hanks & Hoskin, 1987) This is a great challenge to overcome during opioids addiction
and dependence treatment.
Neurobiological Processes in Drug Reward
Now the question is how a super opioid analgesic can create drug addiction, abuse,
and dependence? To understand this neurobiological mechanism, we need to know the
opioid receptor’s location (Figure 2) and functions, the binding affinity of clinical opioid
ligands to their receptors which have already been discussed. From the previous discussion,
activating MOR, DOR and KOR is not only produces analgesic effects but also generates
rewards feelings in the brain. Along with these, we need to the neuroanatomy of the reward
pathway of the brain. The pleasure feelings come by the release of dopamine (DA) into
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midbrain. (Fields & Margolis, 2015) Dopaminergic neurons are the principal source of
DA which are numerously found in midbrain and 90% percent of these are located in
ventral part of the mesencephalon. (Chinta & Andersen, 2005) There are four major
dopamine pathways (Figure 3) by which DA can travel to different areas of the brain and
body and convey messages like pleasure and reward, locomotion, thinking, cognition etc.
(Adinoff, 2004; Fields & Margolis, 2015)
Mesolimbic Pathway: This pathway is involved in pleasure and reward functions.
The dopamine enriched ventral tegmental area (VTA), initiates dopaminergic action
potentials and sends the signals to another area of the brain, nucleus accumbens (NAc)
(Figure 3). The release of dopamine in NAc primarily produces reward and pleasures.
(Adinoff, 2004) Overstimulation of this pathway causes addiction, abuse, and dependence.
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Figure 2. (Benarroch, 2012)The schematic illustration of the locations of opioid
receptors and opioid-synthesizing neurons. The dopaminergic neurons (Figure 3) and
opioid receptors sahred some common locations of brain, specially, the VTA and
NAc, that are reward producing area. Opioids agonists activate the mesolimbic
dopamine pathway as their target receptors and dopamine neurons located same area.
(Adinoff, 2004; Chinta & Andersen, 2005; Kosten & George, 2002)

Mesocortical pathway—dopamine is synthesized in VTA (Figure 3) transmits signals
from the VTA to the prefrontal cortex (PFC) which is involved in memory, motivation
and decision making( Figure 3). (Puig, Rose, Schmidt, & Freund, 2014) The dopamine
15

secretion in this area might be helpful in cognition behavior but it may also elevate the
dopamine level in NAc by the mesolimbic pathway which will drive to addiction. (Yadav
et al., 2014) The inappropriate function of this pathway may generate schizophrenia,
ADHD (Attention Deficit Hyperactivity Disorder), and psychosis. (Puig et al., 2014)
Nigrostriatal pathway—dopamine sends signals from the substantia nigra to the
basal ganglia which are associated with the movement (Figure 3). (Puig et al., 2014)
Inadequate dopamine secretion in this pathway causes Parkinson’s disease (PD).
The tuberoinfundibular pathway is the final dopamine pathway where dopamine is
synthesized in the hypothalamus (Figure 3) and conveyed the signal in the pituitary which
functions on regulating prolactin hormone secretion (Figure 3).
Opioid receptors are also numerously found in ventral area tegmental and nucleus
accumbens (Figure 2), where dopaminergic receptors are located densely. So other than
only to reduce nociception, opioid analgesics also produce euphoria by activating
dopamine pathway and elevating dopamine in the midbrain. (Volkow & McLellan, 2016)
When the mesolimbic pathway is activated, that primarily calls upon euphoric feelings and
continuous euphemism leads to drug addiction, abuse, and drug dependence.(Adinoff,
2004; Chinta & Andersen, 2005) Therefore, the addiction and abuse of opioid drugs will
be increased with the number of prescriptions for these medications.
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Figure 3. (Wikipedia, 2015) The dopaminergic pathways. Mesolimbic pathway
responsible for reward & pleasure feeling which is the principal reason of drug
addiction also; Mesocortical pathway control cognition and activity; Nigrostriatal
pathway controls motor function and tuberoinfundibular pathway maintains
prolactin secretion.(Benarroch, 2012; Wikipedia, 2015)
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Addiction Statistics: Effects on Health and Economics
Opioid prescriptions have been increasing day by day, corresponding with an
increase in opioid abuse. (Kuehn, 2007a) According to the very recent Annual Surveillance
Report of Drug-Related Risks and Outcomes United States, in 2016, nearly 62 million
people either filled or refilled opioids medications at least once, which was 19.1 percent of
patients. (National Center for Injury Prevention and Control (NCIPC), 2017) The same
report also shows: during 2015, opioid drug overdose caused 33,091 deaths and among
them, 15,281 persons died from prescription opioid drug overdose.(National Center for
Injury Prevention and Control (NCIPC), 2017)
The overall addiction scenario can be elucidated from results of the 2016 National
Survey on Drug Use and Health. According to this report, approximately 28.6 million
Americans aged 12 or more use illicit drug categories which include hallucinogens,
inhalants, methamphetamine, and the misuse of prescription pain relievers, tranquilizers,
stimulants, and sedatives. Among drug abusers, 3.3 million are pain relief prescription
misusers. Approximately, in 2016, 11.5 million people (aged 12 or more) misused
prescription pain relievers wherein 97.4 percent are opioid misusers also 1.9 million
misused cocaine. Drug-induced death has been also increasing nearly steadily with time.
In 2014, drug-induced deaths totaled 33,671; in 2015, the total increased 6.9% to 36, 2622
in 2015, and in 2016 it further increased by 5.7%. If we compare between 2006 and 2016,
then the percent of death has been increased shockingly almost 46 percent. (Centers for
Disease Control and Prevention, 2018)
Aside from the health issue, this is an extensive economic burden too. In 2007, the
United States had to expend more than $193 billion for illicit drug use, and surprisingly
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only the prescription opioid abuse cost was approximately $55.7 billion. (Center, 2011;
Kuehn, 2007b) The overall scenario became worse in 2013 compare to 2007—wherein the
economic burden was estimated to be $78.5 billion, which included increased healthcare
and criminal justice costs.(Florence, Zhou, Luo, & Xu, 2016)
Drug Addiction and Treatment
Detoxification of opioid drugs is the primary goal for the treatment of opioid
addiction. The treatment is often possible either by behavioral therapy or pharmacotherapy
or combination of both therapies.(Carroll & Onken, 2005)
Behavioral therapy. Upon based on the previous era, the success of behavioral
therapy is significantly beneficial for treating drug addiction and abuse. There are different
types of behavioral therapies: Cognitive behavioral therapy, contingency management,
community reinforcement approach, motivational enhancement therapy, family behavioral
therapy, and other behavioral approaches have been proved as worthwhile for managing
different types of addictions.(Carroll & Onken, 2005; NIDA, 2018)
Cognitive-behavioral therapy. Relapse is a very common problem for any kind of
treatment against. CBT which includes functional analysis and skill training can
significantly help in the prevention of relapse. (Hendershot, Witkiewitz, George, &
Marlatt, 2011) Patients can learn different techniques to discriminate correct and incorrect
behaviors that help them approaching a problematic situation to abstain from drug abuse.
(Steve, Wendy, & Vic, 2009) Individuals can develop adaptive strategies in unfavorable
social conditions through specific skills such as eliciting knowledge about positive and
negative consequences results of drug abuse, self-control about drug craving, avoiding
possible vulnerable situation etc. (Carroll & Onken, 2005; NIDA, 2018; Steve et al., 2009)
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In some addiction such as cocaine addiction, CBT can be more effective along with
pharmacotherapy. (Carroll et al., 2004)
Contingency management (CM). This behavioral therapy is based on tangible
rewards to encourage the abstinence from drug and the rewards can be either voucherbased reinforcement or prize incentive. (NIDA, 2018) If the drug test such as urine or
breath test confirms drug-negativity, the patient will receive a monetary voucher (voucherbased reinforcement CM) or win cash instead of the voucher (prize incentives based CM),
either way, allows the patient to exchange food, goods or any service to reinforce his/her
drug-free life. (Budney, Higgins, Radonovich, & Novy, 2000) A considerable number of
patients have abstained from opioids or cocaine patients through this CM service. (Petry et
al., 2005; Prendergast, Podus, Finney, Greenwell, & Roll, 2006) Though initially, the
community was concerned about increasing gambling because of prize incentives later it
was confirmed that this service did not promote gambling. (Petry et al., 2006)
Community reinforcement approach (CRA). This behavioral therapy is 24-week
therapy where patients also are rewarded with vouchers for treating cocaine and alcohol
addicted people. (NIDA, 2018) Computer-based CRA is effective for opioids and/or
cocaine-dependent patients. (Higgins et al., 2003) This version train adolescents about
solving the problem, adjustment, communication skills and encouragement to participate
in recreational activities. (Brooks, Ryder, Carise, & Kirby, 2010)
Other behavioral therapy with different strategies also become helpful with or
without pharmacotherapy.
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Pharmacotherapy.
Methadone. Methadone hydrochloride, a MOR agonist, is the first line of opioid
pharmacotherapy which has been used since 1972 upon the approval by the Food and Drug
Administration (FDA).(Institute of Medicine (US) Committee on Federal Regulation of
Methadone Treatment; Rettig RA) Despite this is an opioid agonist but it does not generate
pleasure feeling and the long-lasting pharmacological on the body, makes a drug of choice
for treating opioid addiction and dependence. (Stotts, Dodrill, & Kosten, 2009) The
elimination half-life of methadone is 24-36 hours which is optimal for a longer period of
detoxification. The optimal dosing range for most of the patients is 60-150 mg/daily but
the starting dose range is 20-30 mg/daily which can be gradually increased by 5-10 mg to
catch the standard range. (Institute of Medicine (US) Committee on Federal Regulation of
Methadone Treatment; Rettig RA; Stotts et al., 2009) The daily single dose of methadone
can suppress the opioid withdrawal symptoms. Special precautions must be considered for
the patients with chronic renal diseases and pregnant women and there is a very chance to
grow methadone dependence on the fetus. (Institute of Medicine (US) Committee on
Federal Regulation of Methadone Treatment; Rettig RA) Methadone pharmacotherapy is
more effective with the combination of other behavioral therapy.
Buprenorphine. This synthetic opioid receptor partial agonist is another important
medication for opioid dependence. Buprenorphine does not produce euphoria and can
greatly reduce opioid withdrawal symptoms that can be safely prescribed by primary care
physicians. (Kahan, Srivastava, Ordean, & Cirone, 2011) Two different sublingual tablet
formulations—just buprenorphine and the combination of buprenorphine and naloxone are
available which was first approved by FDA in 2002. (NIDA, 2018; Stotts et al., 2009) The
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maximum recommended dose of buprenorphine is 24 or 36 mg. To reduce possible abuse
liability, buprenorphine and naloxone ration 4:1 often choose over only buprenorphine.
(Mendelson et al., 1999) Commercially buprenorphine to naloxone 2:0.5 or 8:2
combination are available by the brand name Suboxone. (Kahan et al., 2011) One of a
clinical trial showed that the ratio buprenorphine: naloxone, 8:2 and 32:8 mg is better than
2:0.5 mg in reducing heroin replacement therapy. (Mattick, Kimber, Breen, & Davoli,
2008) The treatment becomes more effective when behavioral therapy like extended
weekly counseling is added with Suboxone administration. (Fiellin et al., 2006)
National Institute of Drug Abuse (NIDA) clearly explained, as methadone and
buprenorphine both are opioid drugs, so the treatment with both of these is more likely as
a substitution of one addictive drug to another but in less addictively.
Naltrexone. is an opioid antagonist which is synthetically obtained, can prevent
opioid agonists to bind with their target receptors. (Stotts et al., 2009) It produces neither
rewards nor considerable abuse or addiction which gradually detoxify opioids effects on
the body. Once daily (must be taken with food) 50 mg tablet is a very common treatment
though it can be extended to 100-150 mg in every two-three days—based on physician's
judgment. (Krupitsky, Zvartau, & Woody, 2010; Stotts et al., 2009) Scientists have been
trying to develop sustained release formulation, though some sustained release
formulations were prepared, FDA denied the approvals. (Krupitsky et al., 2010; Stotts et
al., 2009) It has been thought that the long-acting release of naltrexone can improve the
treatment therapy.
All of these treatment options with methadone or buprenorphine detoxify slowly.
The drug-like clonidine, an alpha 2 adrenergic agonist, often as a combination therapy with
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opioid antagonist naltrexone, can undergo rapid opiate detoxifications. (Gowing, Ali, &
White, 2000) Even though this treatment option sounds wonderful but the obtained data
from different studies could not ensure the claimed efficacy for opioid addiction treatment.
(Stotts et al., 2009)
Creating New Opioids
“Prevention is better than treatment”—this is an apothegm; A new opioid analgesic
without or limited abuse liability and with a lower side-effect will be an ideal treatment
option for managing pain. Unfortunately, the opioid choice is limited. It was always being
demanding

to

create

a

new

opioid

analgesic

with

less

adverse

effect.

The first single opioid compound, morphine, was isolated from the tarry poppy seed juice
by pharmacist Friedrich Wilhelm Adam Serturner in 1805. (Krishnamurti & Rao, 2016)
After 120 years long research of isolation, morphine’s structure was established in 1925 by
Sir Robert Robinson and it took around 30 years to find out the laboratory total synthesis
of morphine which was developed by Marshall D. Gates.(Bentley, 1987; Gates & Tschudi,
1956) Structural modification in some important positions by analyzing structure-activity
relationships (SARs) in 4,5a-epoxymorphinan skeleton (Figure 3), in previous years,
remarkably helped to create new opioids. (S. Majumdar et al., 2012; Pasternak & Pan,
2013)
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Figure 4. 4,5α-epoxymorphinan template (left) and morphine (right). The SARs of
morphinan compounds have been primarily created by altering substituents at the three R
groups. (Pasternak & Pan, 2013)

Table 2
Examples of Some 4,5α-epoxymorphinan Compound’s SARs Modification at Different
Carbon. (Pasternak & Pan, 2013)
Compounds
Morphine
Codeine
Morphine-6-sulfate
Morphine-6βglucuronide
Heroin

R1
H
CH3
H
H

R2
CH3
CH3
CH3
CH3

R3
H
H
SO3
Glucuronide

CH3
Acetyl

Acetyl
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Structural features. The 4,5α-epoxymorphinan compounds (Table 2) have some
common structural features: a benzene ring (A), cyclohexane rings (B and C) which are
partially unsaturated, a piperidine ring (D) and with a dihydrofuran ring (E). A hydroxyl
group especially at the C-3 position (Figure 4), play a vital role for narcotic analgesic
effects, loss of free hydroxyl group significantly reduce the affinity of an opioid to MOR
or it may produce some other effects such anti-tussive effect of codeine. (Pert, Pasternak,
& Snyder, 1973) Change at C-6 (Figure 4) with the different group also can affect the
overall pharmacological properties—such as when hydroxyl groups of morphine are
replaced by acetyl at both C-3 and C-6 positions, it elevates the lipophilicity and enhances
blood-brain barrier (BBB) permeability.(DeRuiter, Fall 2000; Pasternak & Pan, 2013) The
reduction of the double bond at C7-C8 (Figure 4) yields dihydromorphine, further
substitution at C-14 by a hydroxyl group and oxidation of hydroxyl group at C-6 produces
oxymorphone with more activity. A basic, tertiary amine at position 17 (Figure 4) plays an
important role too, substitution of oxymorphone’s N-methyl group with an allyl group,
makes an opioid antagonist, naloxone, and if replacement happens by an ethylcyclopropane
it yields another opioid antagonist, naltrexone. A number of other modifications also have
developed several different clinical opiates, including both antagonists and agonists (Table
2).
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Chapter 2
A Novel Atypical Mu Opioid Receptor Agonist 3-Iodobenzoylnaltrexamide
(IBNtxA)
Scientists have been aspiring to generate novel opioid compounds with better
analgesia but limited side-effects. Recently when a group of scientists from Memorial
Sloan-Kettering Cancer Center, New York, had been synthesizing radiolabeled derivatives
of the opiates, they found an atypical novel opiate, named- IBNtxA with wonderful
pharmacological characteristics. (Susruta Majumdar, Burgman, et al., 2011; Susruta
Majumdar, Grinnell, et al., 2011; S. Majumdar et al., 2012) This molecule was synthesized
as a 6β-naltrexamine derivative which is an analog of naltrexone. When they substituted
R3 position with 3-iodobenzene, R1 with methylcyclopropane and R2 with hydrogen, they
found – IBNtxA (Figure 5).(S. Majumdar et al., 2012) Their investigation found—IBNtxA
is potent than morphine when they tested analgesic properties by tail flick method, with
lowered side-effects such as no respiratory effects, no physical dependence, and no place
preference when they tested single dose.(Susruta Majumdar, Grinnell, et al., 2011) IBNtxA
possibly signals through truncated MOR splice variants—exon 11-associated 6
transmembrane region splice variants (6TM/E11) but the role of 6TM/E11 is not wellestablished though it’s been hypothesized that it can affect the analgesic signaling of some
MOR agonists. (Lu et al., 2015; Susruta Majumdar, Grinnell, et al., 2011)
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4,5-epoxymorphinan skeleton

Naltrexone

IBNtxA

Figure 5. SARs of 4,5-epoxymorphinan skeleton wherein the replacement of
R1 at N-17 position by methyl cyclopropane, R2 at C-3 position by hydrogen
and double bond with oxygen at C-6 position, produces opioid antagonist,
naltrexone. Change in 4,5-epoxymorphinan skeleton at R1 and R2 same as
naltrexone but replacement of R3 by 3-idobenzene creates an atypical mu
opioid receptor agonist IBNtxA which is a derivative of 6β-naltrexamine with
higher analgesic effects but limited side effects than morphine and highly
selective to 6TM/E11 MOR splice variant.(S. Majumdar et al., 2012)
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Recent molecular dynamics simulations studies (led by Dr. Chun Wu) on morphine
and IBNtxA with 7-transmembrane (7TM) and 6-transmembrane (6TM) of MOR splice
variants, has confirmed that morphine is incapable to activate 6TM where IBNtxA can
activate but the interaction between IBNtxA and 6TM/E11 and 7TM splice variants
remains unclear.(Sader, Anant, & Wu, 2018) This analysis also confirmed that IBNtxA has
stronger binding properties to 7TM than morphine.(Sader et al., 2018) The loss of exon
11-associated MOR splice variants in knock-out (KO) mice, caused loss of analgesia for
IBNtxA but the analgesic effect of morphine was unchanged and when exon 1-associated
splice variants, DOR and KOR were knocked out, morphine was unresponsive to those
animals but IBNtxA expressed, analgesia—both event indicates that IBNtxA may response
through 6TM/E11. (Susruta Majumdar, Grinnell, et al., 2011)
In this collaborative pilot projects we investigated: Analgesic properties of IBNtxA
other than tail flick method, expanded abuse liability testing of IBNtxA using conditioned
place preference (CPP), potential anti-addictive impact of IBNtxA by measuring its effects
on morphine CPP, whether IBNtxA affects morphine-induced locomotion, the subjective
effects of IBNtxA (MOR/KOR/DOR signaling?) by drug discrimination techniques and
provide a foundation for future studies dissecting the effects of IBNtxA on other receptors
and evaluating analogues of IBNtxA.
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Materials and Methods
Animal. All experiments used male CD-1 mice or C57BL/6 mice obtained from
Charles River Laboratories. All animals housed in the temperature- and humiditycontrolled Cooper Medical School of Rowan University vivarium, a barrier facility, under
a 12 h light/dark cycle (lights on at 0700, off at 1900). Mice were group housed in
polycarbonate cages with ad libitum food and water and enrichment provided by paper
Bio-Huts and/or nestlets. Mice arrived at the facility approximately 28 days of age and
were allowed to equilibrate to the facility for a minimum of seven days before beginning
testing.
CD-1 mice. CD-1 laboratory mice (Figure 6) are inexpensive and widely used in
biomedical and pharmaceutical research. Most of the currently used mice are the progeny
of nine Swiss mice, two male and seven female albino mice, which were imported to the
USA in 1926 by Dr. Clara Lynch of the Rockefeller Institute for Medical Research, now
named Rockefeller University.(Chia, Achilli, Festing, & Fisher, 2005) In 1948, new
Ha/ICR mice were initiated from previously imported Rockefeller “Swiss” mice at the
Institute for Cancer Research (ICR) in Philadelphia.(Chia et al., 2005)
Characteristics of ICR (CD-1®) Mice: CD-1 (Figure 6) mice are white in color;
usually they are docile and these mice grow with time which became maximum after fifteen
weeks though the growth rate and weight gain are higher in male than female.(River, 2018)
We started experiments when animals were around 35 days old, at that point we
found the average weight of mice—approximately 34-36 gm. When we were working with
CD-1 mice, in our observation, they were usually easy to handle but very first week they
were outrageous, especially during drug administration. The reason behind their aggressive
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behavior during the first few days—the time need for adaptation to human and drug
administration.
C57BL/6 mice. This is a typical inbred strain, most widely genetically modified
laboratory mice for biomedical, pharmaceutical, translational science or any animal study
research due to their availability and robustness. This strain was first developed by C.C.
Little in 1921 which was eventually handed over to Charles River in 1974 from NIH. (Chia
et al., 2005; River, 2018; Sarna et al., 2000)
They are deep brown or almost black (Figure 7), highly sensitive to noise and
odors; not docile like CD-1 mice and more likely to bite. They are barbering in nature, and
dominant mice can remove hair and whisker of housemates. (Sarna et al., 2000) (Willott,
Erway, Archer, & Harrison, 1995) Notwithstanding most of the different strains, these mice
are highly susceptible to addiction, atherosclerosis and age-related hearing loss. (Willott et
al., 1995) Like CD-1 mice, this strain also grows with time, reaching full weight after
fifteen weeks; we started to weigh them after five weeks, and the average approximate
weight was 18-22 g.
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Figure 6:(Taconic Biosciences, 2018) Image of CD-1 outbred mouse, white in color
and usually docile in behavior. These mice have been widely used in biomedical
research. They are normal wild type mice, grow over time and gains maximum weight
in fifteen weeks. (River, 2018)

Figure 4: (LABORATORY, 2018) Stock photo of C57 mouse, genetically designed
animal. This strain is deep brown or almost black, noise and odors sensitive; are highly
susceptible to addiction, atherosclerosis and age-related hearing loss. They are barbering
in nature, prone to engage fighting with inmates, resulting hair removal and sometimes
possible injuries. (River, 2018; Sarna, Dyck, & Whishaw, 2000; Zurita et al., 2011)
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Drugs. IBNtxA was synthesized at Rowan University by the laboratory of Dr.
Gustavo Moura-Letts, who developed a three-step synthesis starting from naltrexone
purchased from Tocris. Morphine sulfate was purchased from Henry Schein. Cocaine HCl
was purchased from Sigma. Naloxone was purchased from Tocris. The other substances
that were used—naloxone, buprenorphine, methadone, U50,(488), TAN-67 (SB-205,607).
All drugs were delivered via intraperitoneal (i.p.) injection at a volume of 10
mL/kg. Drug dilutions were premixed to provide a given mg/kg dose when given an
injection volume scaled to mouse body weight, measured prior to every test. For example,
a 35 g mouse would receive a 1 mg/kg drug dose via the injection of a 0.35 mL volume of
a 0.1 mg/mL drug solution. IBNtxA was delivered in a 10% DMSO vehicle, prepared via
stepwise mixing with 1% 6M HCl, 10% dimethyl sulfoxide (DMSO), and 89%
physiological saline. All other drugs were readily dissolved in physiological saline, or 10%
DMSO vehicle. All the drugs were kept secure inside a locker with a regulated inventory
procedure under the control Dr. Bradford Fischer, who holds controlled substances licenses
from the State of New Jersey and the U.S. Drug Enforcement Agency.
Conditioned Place Preference (CPP)
Apparatus. The conditioned place preference (CPP) paradigm is a standard
preclinical behavioral analyzing model which has been widely used for the investigations
of abuse and addictions for illicit drugs, food, sex, etc. (Prus, James, & Rosecrans, 2009)
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Figure 8: Photo of new CPP apparatus from our research lab, where in white chamber and
black chamber for drug or vehicle-paired side and gray chamber in the middle is the neutral
zone. The locomotor activity of animals is tracked by infrared and then signal is sent to
MED-PC software to analyze and present on the monitor.
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For IBNtxA-related CPP studies, we used modular CPP chambers from Stoelting
for use with Any-Maze software. These chambers featured: with two rectangular shapes
compartments which are connected through one small central compartment (Figure 8).
Rectangular shaped compartments are either circular grid or square grid flooring with the
similar marked wall. For M. vaccae-related studies, we used dedicated CPP chambers from
Med-Associates for use with MedPC software. These chambers featured: three
compartments in a rectangular box-shaped chamber, characterized by the white and black
wall for two adjacent chambers of the center chamber which has a gray color wall (Figure
8). The center compartment doesn’t have specific features, neither paired with drug nor
with the vehicle, and two gates between two adjacent compartments connected with this
compartment which allows animals to move freely.
General procedure. Initial preference: Before starting the training, we took
consideration whether animals have any initial preference to any chamber. For instance,
we named two different compartments, suppose, circular grid compartment and square grid
compartment. Prior to conditioning, we calculated the ratio of time spent in an individual
compartment. Usually, in the unbiased experimental procedure, the drug-paired, and
vehicle paired compartments are assigned randomly regardless of initial preference score
but in a biased CPP study, the compartment which is least preferred by subject is paired
with the drug for that individual. (Huston, Silva, Topic, & Müller, 2013)
Drug conditioning: during conditioning (Figure 10), which also can be defined as
training or acquisition, animals are repeatedly and alternately exposed to either the
investigative drug while confined to one compartment or vehicle while confined to the
other compartment. (Huston et al., 2013)
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After assigned drug side and vehicle side for the individual, the mouse was confined
to drug-paired compartment after injecting with drug and, in alternate sessions, the same
animal was confined to vehicle paired compartment after getting vehicle injections (Figure
10). Before drug/vehicle administration individual animal’s health and behavioral
parameters—food intakes, percent of weight gained or lost, any injury due to fighting with
mates, any infection for any possible reason, quality of stool, hyper or hypo activity—were
noted and scored. Any animal which with considerable behavioral or health issue like
sickness was separated and excluded from further experiments. The animals with good
physiological conditions where then inject and placed inside pre-cleaned and proper-set the
CPP chamber. For the development of a place preference, animals were trained as long as
10 days acquisition period(Figure 9). Every time before the animal was placed inside CPP
chamber, all apparatus was cleaned with 70% IPA and the beds were washed with water
then cleaned by 70% IPA to eradicate microorganisms and get rid of from any possible
previous odors.
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Figure 95: The schematic illustration of CPP test. The animals arrive in vivarium of Cooper
Medical School of Rowan University (CMSRU) and have been kept for five days. After
two days of daily handling to make them comfortable with researchers, they are being
placed in CPP chambers for initial preference for two sessions then ten days (ten sessions)
CPP training. After successfully completing training they have been tested for CPP
expression and finally stress/drug-induced reinstatement test followed by CPP extinction.
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Figure 10. The general schematic presentation of CPP procedure. This figure was
adapted from (Fernandes & Fulton, 2016).
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The trained mice were tested to analyze place preference score through CPP
expression trial, during this phase subjects did not receive any injection, and they were free
to move any compartment of entire apparatus (Figure 10).
After completing CPP acquisition and expression (Figure 9), the conditioned mice
were repeatedly exposed to all CPP compartments freely in absence of drug or vehicle.
Three days of continuous trials led animals to loss of place preference—known as CPP
extinction(Figure 10). (Prus et al., 2009)
CPP reinstatement (Figure 9 &10), followed by extinction, can be induced by either
re-exposure to the drug which is also defined as drug-primed reinstatement or stress. Our
pilot project had analyzed drug reinstatement study through both ways which were used as
a model of relapse.
Two methods are widely followed for behavioral studies to investigate stressinduced reinstatement: forced swim and foot-shock; our studies were designed for forced
swim stress-induced reinstatement. (Can et al., 2012; Yavin Shaham, Uri Shalev, Lin Lu,
Harriet de Wit, & Jane Stewart, 2003) Mice were placed in an inescapable cylindrical tank
which was 30 cm height x 20 cm diameters and constructed of transparent Plexiglas. The
water level was marked on the tank which was more than 15 cm but less than 20 cm, and
the water temperature was maintained 25 to 28 degrees Celsius. One mouse was kept for
force swim in one cylinder for 5-6 minutes and then was dried and placed in CPP. The
stresses mice were used to test the anti-stress, anti-anxiety as well as anti-addiction effects
of drugs.
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Statistical analysis. A preference score is calculated from the difference between
the time spent in the drug-paired compartment before CPP training and the time spent in
the drug-paired compartment on test day after CPP training—during CPP expression.
𝑃𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑆𝑐𝑜𝑟𝑒 = 𝑡𝑖𝑚𝑒𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 − 𝑡𝑖𝑚𝑒𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑠𝑖𝑑𝑒

Drug Discrimination
Animal and drug. CD-1 male mice (Figure 6)were used for drug discrimination
studies. Mice were food restricted for 6-12 hours prior to experiments but they have
adequate access to water and air. Two group animal were used: one group was trained with
morphine 3mg/kg and DMSO vehicle (1% 6M HCl, 10% DMSO and 89% saline), welltrained animals were tested with novel drug (1-3 mg/kg IBNtxA and 0.1, 1, 3 and 10mg/kg
morphine and another group received training with 3mg/kg IBNtxA and vehicle, and
trained animals were tested with morphine (1-30 mg/kg), buprenorphine (0.1-3 mg/kg) a
non-selective MOR/DOR/KOR agonist and fentanyl (0.01-0.3 mg/kg) a MOR-1 agonist,
U50,488 a KOR-selective agonist, (1-20 mg/kg), a DOR-selective agonist, TAN-67 (SB205,607) morphine (1- 30 mg/kg), a MOR-1 agonist.
Apparatus. Drug discrimination study was designed in the murine model, to
understand whether the subjective effects of IBNtxA were similar to morphine. The DD
apparatus has consisted of eight small boxes (Figure 11) which were designed by cutting
edge technology. Each small box made of acrylic transparent glass which was covered by
a spacious larger wooden box. All boxes were connected via different cables with
computers where MED-PC software converted the animals’ behavioral activity to data and
showed on the monitor.
Each box had two nose poke holes: one for drug and another one for vehicle side
(Figure 11). When animals nose poked on either side, an infrared beam was broken and a
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signal was sent to the operating MED-PC software. During the experimental session, boxes
were enclosed to isolate animals from other outside environmental factors, but during
confinement, they received adequate air and light. A liquid dipper was located between the
two nose poke holes, connected via tubing to a syringe (Figure 11) that discharged vanilla
Ensure, a palatable food reward, for 3 seconds (delivering an approximate 0.1 mL volume)
as a reward when animals earned a programmed reward. To earn the reward, animals were
required to complete a specific pattern of correct responses: the required number of correct
responses to earn a reward is known as the fixed ratio (FR). An FR10 training paradigm,
for example, requires that the animal complete 10 correct nose pokes in a row to earn a
reward. MED-PC software regulated the total system.
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Figure 61. Schematic illustration of drug discrimination apparatus. The left hole is
vehicle-paired; if animals knock this hole on vehicle-training session is considered as
correct response and the right hole is drug-paired; on drug-training session if animals
knock this hole, is considered as correct response. For every ten correct nose pokes,
animals receive one single reward which is three seconds Ensure Plus syrup discharge
through reward spout. During substitution test day any nose pokes to either side are
considered for reward. The speaker on top of image is a sound generator which
produces a tone during reward delivery.
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Procedure. Animals were food restricted up to 24h before training or testing.
During food restriction, animals have ad lib access to water. The weight of food-restricted
animals was measured, and other visible health parameters were evaluated, including stool,
appearances, and physical hyper/hypo-activities. After setting everything based on
protocol, animals were injected and placed inside the boxes for training or test.
In our FR schedule, the subject must complete a set number of correct responses
during the training period to obtain one reward, and our research considered maximum ten
correct responses as FR to get a single reward. Fixed ratio ten means if animals knock ten
times to correct side they will get one reward. For elucidation, when a mouse received
training drug, the correct responses were considered if that animal hit on drug side and
there was no reward for the incorrect response that means vehicle side response. The
procedure was almost the same as the training session for substitute test except animals
were free to choose any side for their rewards.
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Figure 72. Outline of drug discrimination training. From the top of this image, after
getting injection (i.p.) animals are placed inside DD box, and after 15 mins stimuli
appears. Subject receives reward of three seconds liquid food dispense through reward
spout for every ten correct responses. The training session becomes automatically end,
either getting 50 rewards or after 60 mins or both.
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Total procedure can be showed as this way (Figure 12): Injection ( i.p.) > stimuli
present ( after 15 minutes ) > response to correct side (FR=10) > Reward ( 3 sec chocolate
syrup discharge ) > end of single training session ( Either after 50 reward and/or 60 minutes
) . (Solinas, Panlilio, Justinova, Yasar, & Goldberg, 2006) At the end of each day
experiment, all apparatus was cleaned with animal sanitary napkins, 70% IPA and water.
Two groups animals—each group contained eight CD-1 mice has been trained. One
group was trained with vehicle (1% 6M HCl, 10% DMSO and 89% NaCl) and morphine
3 mg/kg. To train mice properly and unbiasedly, the pattern of training was always being
changed in each week for overcoming any possible effect of training schedule pattern
which might affect discrimination study.
The animals which could not reach the standard training with minimal 80% initial
correct, 80% total correct response and 80% reward were excluded beforehand.
Furthermore, every animal was kept in close observation for any health issue such as
weight loss, stool condition, any possible injuries etc. Sick animals were separated from
other mates and treated with required medicines. The animals with better health were
trained and tested only.
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Statistical analysis. Following equations were used for analysis:
For training.
% 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
=(
) × 100
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠

% 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
=(
) × 100
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠

For the substitution test.
% 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
=(
) × 100
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝑇𝑜𝑡𝑎𝑙 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
% 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒
=(

𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
) × 100
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠

For the rate of response. Other than only considering percent of the response to
drug/vehicle side, the response rate is also a crucial factor for drug discrimination study. A
consistent and proper response rate confirmed the appropriate training dose and the
possible range of dose which might be tested for a drug. Furthermore, the rate of response
helped to analyze some certain behavioral study of animals such as sedation, hyperactivity
or hypoactivity etc. for DD study. ("Frontiers in Neuroscience," 2009)
The simple equation is as follows:
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑒 =

𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑡𝑖𝑚𝑒
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Analgesic Test: Hot Plate Technique
Animal and drug. Male CD-1 mice, 40-50 days old, obtained from Charles River,
had free access to food and water, exposed to a light-dark cycle of 12 h were used for this
test.
Hot plate test was used to evaluate the analgesia of IBNtxA and then to compare
with morphine. Novel drug IBNtxA 1 mg/kg and 3 mg/kg and morphine 10mg/kg were
administrated by intraperitoneal (i.p.) injection. Three groups of animals, each containing
eight animals, were assigned to receive 1 mg/kg IBNtxA, 3 mg/kg IBNtxA or 10 mg/kg
morphine.
Apparatus. The hot plate analgesia meter (Columbus Instruments, OH, U.S.A.) for
small laboratory animals were used for this analgesic test. The hot plate could continuously
provide 55°C temperature on an aluminum surface, with a digital built-in thermometer to
maintain surface temperature to 0.1 °C precision and a timer with a 0.1 sec precision. The
square shaped surface plate was enclosed by a clear acrylic cage to confine animals during
testing. Pushes on start/stop button related to the timer, which displayed the time on the
screen which was recorded manually.
Procedure. The hot plate was set at 56 °C to observe the effects of drugs on animals.
Certain behavioral changes, paw licking, flutter, and jumping, were considered as an
animal’s pain feeling. (Rezaee-Asl, Sabour, Nikoui, Ostadhadi, & Bakhtiarian, 2014)
Latency time after placing mice on the metallic hot plate provided the threshold level of
animals. Prior to injecting the drug, each mouse was weighed and tested for two baseline
studies where the animal was not injected with any drug or vehicle. After baseline studies,
testing drug was administrated and animals were placed on hot plate in 15, 30, 45, 60,
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and/or 75/90 minutes time intervals to collect the latency time. If any behavioral change
like paw licking, flutter or jumping had been observed, the mouse was immediately
removed from hot plate and latency time was recorded. Animals were removed from hot
plate after 20 seconds even though there was no considerable behavioral change to avoid
tissue damage and this specific time is known as maximum latency time. Any animal which
showed more latency time more than 20 seconds was excluded from further investigation.
(Menéndez, Lastra, Hidalgo, & Baamonde, 2002; Rezaee-Asl et al., 2014)
Statistical Analysis. The anti-nociceptive effect for each dose was calculated as the
% of the Maximal Possible Effect (% MPE) using the following formula:
𝐿𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑢𝑔 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑎𝑟𝑡𝑖𝑜𝑛−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠
)
{ 𝑀𝑎𝑥𝑖𝑚𝑎𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 (20)−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠}

% 𝑀𝑃𝐸 = (

× 100

Open-Field Locomotion Test
Animal and drug. Male C57 mice were used and IBNtxA 3 mg/kg and and
morphine 10mg/kg were administrated by intraperitoneal (i.p.) injection. There are two
types of vehicles had been used: 1% 6M HCl, 10% dimethyl sulfoxide (DMSO), and 89%
physiological saline (DMSO vehicle ) and only physiological saline (0.9 % NaCl). Three
groups of animals, each containing eight animals, were assigned to receive 1 mg/kg
IBNtxA, 3 mg/kg IBNtxA or 10 mg/kg morphine.
Apparatus. The open-field locomotor test was determined by using 40*40*35 cm
Plexiglas® open-field (Figure 13) and a camera mounted overhead, recorded and tracked
locomotion of animals which was connected to the Any-maze behavioral analysis software
of a computer. The field was divided by two regions: center region by 20*20 cm and rest
of area for outer regions.
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Figure 83. Schematic presentation of open-field box which is 404035 cm
Plexiglas® with a camera on the top of box is connected through cable with computer
operated Any-maze software which tracks and analyzes animal’s locomotor activity.
The total open-field is separated into two zones—center zone (2020 cm) and outer
zone.
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Procedure. The procedure was simple—every animal was pre-weighed before
treated with vehicle or drug then was placed inside the confined open-field for 40 mins to
investigate the locomotor activity.
To understand the effect of novel drug (IBNtxA) on morphine-induced locomotion,
at first animals were injected with either IBNtxA or DMSO vehicle (1% 6 M HCl, 10%
DMSO, 89% saline), were kept in home cages for 15 minutes then they were injected (i.p.)
with morphine and were placed on field for 40 mins. The wall of boxes and beds were
cleaned and dried every time for each animal’s testing with 70% IPA to avoid possible
microorganism contamination as well as previous any kind of smell.
Statistical Analysis. The total distance, time in the center zone, and time in outer
zones were collected for further behavioral analysis. Total distance traveled by animals
was statically analyzed using GraphPad Prism 6.0 statistical analysis software.
Results
Hot plate Analgesic Test: IBNtxA is more potent than morphine. According to
the description above, the three group (n=8) of C-57 mice were injected intraperitoneally
with two different strength of IBNtxA—1 mg/kg and morphine 10 mg/kg. When we
compared the percent maximal possible effect (MPE) in the hotplate analgesic test of novel
IBNtxA with classical MOR agonist analgesic morphine, we found that 3 mg/kg IBNtxA
was more potent than 10 mg/kg morphine but 1 mg/kg IBNtxA did not show any
considerable efficacy (Figure 14). Both IBNtxA 3mg/kg and morphine 10 mg/kg exhibited
their maximum pharmacological action after 30 mins, wherein novel drug showed more
than threefold more analgesia than control drug. In term of duration of action, the
therapeutic curve indicated that morphine had a longer analgesic effect than IBNtxA.
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Morphine took more than 90 mins to be reduced in zero percent MPE but IBNtxA took 60
mins. The possible reasons behind the difference between the duration of action between
two drugs—half-life, protein bindings, and metabolism.
Conditioned Place Preference: IBNtxA does not induce a place preference
Using the method described previously, nine groups of C57 mice (n=6-15 for each group)
were tested for morphine- or IBNtxA mediated place preference. Animals were
administered (i.p.) morphine, IBNtxA, or vehicle in a two-compartment CPP chamber. One
group received normal biological saline, four groups received different doses (0.1, 0.3, 1
and 3 mg/kg) of IBNtxA, another four groups of mice received four different doses (1, 3,
10, and 20 mg/kg) of morphine. Animals were assigned for drugs or saline administration
in an unbiased method. According to our research plan, we compared the preference score
of among control (saline), well-known MOR analgesic (morphine) and the novel atypical
MOR agonist (IBNtxA). IBNtxA did not show any statistically significant preference score
compared to morphine (Figure 15). The morphine-induced place preference score of was
initially increasing with the increase of dose which decreased later in higher dose: there
was no preference for 1 mg/kg, little preference score but nonsignificant for 3 mg/kg and
high preference score for 10 mg/kg which was more than 20 mg/kg morphine dose. The
comparison of preference score between 3 mg/kg IBNtxA and 10 mg/kg morphine
(analgesic test showed both are effective and equivalent) exhibited significant CPP score
difference wherein IBNtxA did not exhibit preference but morphine had highest preference
score (Figure 15).
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Conditioned Place Preference: IBNtxA reduces morphine-induced CPP. To
investigate the effect of IBNtxA on morphine-induced CPP, three groups (n=10-11 each)
of animals were used. Where all animals received morphine 10 mg/kg, but the pretreatment substances were different for the three groups. The pretreatment time was 15
mins prior to inject (i.p.) morphine wherein first group was pre-injected with saline, the
second group was pretreated with IBNtxA 1 mg/kg and the third group were pre-injected
with IBNtxA 3 mg/kg. The result showed that mice those were pretreated with saline and
IBNtxA, showed a preference for the drug side which indicated, IBNtxA 1mg/kg did not
reduce the preference score (Figure 16). Animals which were pre-treated with IBNtxA 3
mg/kg, did not show any significant preference score which indicated that IBNtxA 3mg/kg
significantly reduced the morphine-induced conditioned place preference score (Figure
16).
Open-field locomotor test: IBNtxA attenuated morphine-induced
hyperlocomotion
Four groups (n= 6-11 per group) of C57 mice were used for this investigation. There were
two stages of injection: pre-injection and post-injection—pre-injection were administrated
15 mins prior to get post-injection. Four groups of animals were assigned drug and vehicle
according to the following ways—Group-A: pre-injection with IBNtxA 3 mg/kg and postinjection with morphine 10 mg/kg, Group-B: pre-injection with DMSO vehicle and postinjection with morphine 10 mg/kg, Group-C: pre-injection with IBNtxA and post-injection
with saline and Group-D: pre-treatment with DMSO vehicle and post-injection with saline.
The locomotor activity of Group-A, C and D were lower, but Group-B showed higher
locomotor activity which clearly exhibited the morphine-induced hyperlocomotion (Figure
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17). The animals which were pre-treated with IBNtxA 3 mg/kg prior to receiving morphine
10 mg/kg, showed normal locomotor activity like Group-C and D wherein animals were
treated with vehicle, saline or IBNtxA(Figure 17). Further data analysis among all groups
indicated that IBNtxA reduced the hyperlocomotion activity induced by morphine 10
mg/kg, moreover, IBNtxA did not have hyperlocomotion (Figure 17).
Drug Discrimination Study: IBNtxA partially substitutes for morphine
According to the method mentioned earlier, animals (n=8) were trained with morphine 3
mg/kg were tested for drug substitution of IBNtxA. It took almost 60 days to train animals
well and then in each week one single dose of the even for the same drug was tested. When
animals were well-trained (more than 80% correct response), they were tested with DMSO
vehicle, morphine (0.3, 1, 3, 10 mg/kg) and IBNtxA (effective analgesic dose 3 mg/kg).
The response to drug side was increased with the increase of a dose of morphine (Figure
18). The animals when pre-injected with naloxone 1 mg/kg before injecting morphine 3
mg/kg and asked to choose drug or vehicle side and they did not respond to the morphine
side (Figure 18) which indicated that naloxone blocked the morphine to bind with target
receptors. Finally, animals were tested for discriminating of IBNtxA with morphine and
the result showed IBNtxA partially substituted morphine (Figure 18).
The response rate is critical to evaluate alongside the substitution results. Drug
doses that substantially suppress behavioral responding can complicate interpretation of
substitution results. The average response rates during the last four days of training with
both morphine and vehicle were very similar, but slower than the average response rates
of vehicle and low doses of morhine during substitution tests. During the test with
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morphine, the rate of response curve was fallen downward when the dose was increased
from 1 mg/kg to 10 mg kg but lower dose morphine caused high response rate (Figure 19).
Discussion
IBNtxA has a powerful analgesic effect, comparable to morphine, which is very
crucial for alleviating moderate to severe pain. The patients with severe pain—i.e., those
with cancer or major surgery—need potent analgesic. IBNtxA was effective at a lower dose
compared to morphine. Our hot plate study has confirmed that IBNtxA induced analgesia
comparable to morphine at a dose that did not produce conditioned place preference
(Figure 14). A drug with potent analgesic effect with no or minimum addiction is very
important to reduce addiction, abuse, and dependence. Place preference score, in a rodent
model, has been widely used to correlate with the addiction ability of a drug. Our
investigation expanded the abuse liability studies of IBNtxA by using preference score
induced different doses which were compared with different doses of morphine-induced
place preference scores (Figure 15). Since IBNtxA did not produce any considerable place
preference, it might not have an addiction or abuse liability.
There are very few drugs such as buprenorphine, naltrexone and methadone are
available for opioid replacement therapy or adjuvant therapy for opioid addiction. Our
research has confirmed that IBNtxA significantly reduces the morphine-induced CPP
(Figure 15) which is correlated with the anti-addiction potentiality of IBNtxA. Moreover,
we found that it also suppressed the morphine-induced hyperlocomotion (Figure 17) that
is also some sort of related to drug seeking behavior. Since IBNtxA suppresses both CPP
and hyperlocomotion which are induced by morphine, so it might have potent anti-
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addiction properties which could be used as an opioid replacement therapy for opioid
addiction pharmacotherapy.
As a novel atypical MOR agonist, we have been investigating how IBNtxA
signaling through, what are the
subjective effects of this drug. The drug discrimination study which we have been
conducting to find out these questions. The part of this study has already been completed,
showed that IBNtxA partially substituted morphine (Figure 18). The previous studies
conjected that it might be signaling through truncated E11/6TM splice variant of mu opioid
receptor, but morphine does not signal through this splice variant, rather, it signals by full
MOR. So, to know more about IBNtxA’s subjective effects, one group of animals is
currently being trained to discriminate 3 mg/kg IBNtxA from DMSO vehicle. Once fully
trained, they will be tested for drug substitution with morphine (1-30 mg/kg),
buprenorphine (0.1-3 mg/kg), fentanyl (0.01-0.3 mg/kg), U50,488 (1-20 mg/kg), and TAN67 (SB-205,607, 1-20 mg/kg). All the substitute results will soon confirm the subjective
effects of IBNtxA.
Conclusions
The opioid epidemic is now a widely known term for America as well as other
parts of the world. America has been fighting against this crisis for a longer time. Our
collaborative research has confirmed that IBNtxA does not have possible addiction liability
through our extended CPP test. Moreover, we also confirmed the possible anti-addiction
ability of this drug along reconfirmed the stronger analgesic effect of IBNtxA. We are very
close to finding out the subjective effect of this molecule which will be providing more
obvious information for understanding IBNtxA signaling mechanism. A new clinical
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opioid analgesic with higher potentiality but lower side-effect could be a groundbreaking
medicine to fight against opioid addiction.
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Figure 94. IBNtxA hot plate analgesia in CD-1 mice. Three groups of mice (n = 8 each)
received 1 mg/kg IBNtxA, 3 mg/kg IBNtxA, or 10 mg/kg morphine i.p., and were tested
independently on a 56° C hot plate. 30 min after injection (time = 0 min), 3 mg/kg IBNtxA
and 10 mg/kg morphine showed peak analgesic effects. 1 mg/kg IBNtxA did not show an
analgesic effect. From the dose-response above, it can be inferred that 3 mg/kg IBNtxA is
comparable in analgesic potency to 10 mg/kg morphine. Results were evaluated as

𝐿𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑢𝑔 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑎𝑟𝑡𝑖𝑜𝑛−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠
)
{ 𝑀𝑎𝑥𝑖𝑚𝑎𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 (20)−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠}

% 𝑀𝑃𝐸 = (
100.

All data are presented as means ± SEM.
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Figure 105. CPP scores comparison among saline, morphine, and IBNtxA. One group
(each group contains n=6-15) mice were treated with saline which did not have a preference
score. Four groups animals received four different doses of IBNtxA and other four groups
mice received four doses of morphine. The initial preference was for three sessions and
then training for 10 sessions after that CPP expression for just single session and every
session of each stage was for 30 mins. The result confirmed that IBNtxA (green color) did
not have a preference when was compared with saline’s and morphine’s (red color )
preference score. The score was calculated by subtracting the pre-training preference score
(drug-paired chamber) from the preference score (drug-paired chamber) of the posttraining test. Data are presented as means ± SEM. *p < 0.05, repeated-measures 2-way
ANOVA with Sidak's multiple comparisons test.
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Figure 116. The effect of IBNtxA on morphine-induced place preference. Three groups
of animals (n=10-11 per group) which were pretreated with DMSO vehicle, 1 mg/kg
IBNtxA, or 3 mg/kg IBNtxA prior to every 10 mg/kg morphine administration during a
10-day training regimen. After training, CPP expression was measured in a 30-minute
session in which animals had free access to both drug- and vehicle-paired chambers. 1
mg/kg IBNtxA did not reduce morphine-induced CPP, but mice pre-treated with 3 mg/kg
IBNtxA prior to receiving 10 mg/kg morphine showed no morphine place preference.
These results indicate that 3 mg/kg IBNtxA attenuated the morphine-induced CPP
expression. The data are presenting with means ± SEM. *p < 0.05, repeated-measures 2way ANOVA with Sidak's multiple comparisons test.
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Figure 12. Drugs and/or vehicle-induced locomotor activity. Four groups of animals (n=
6-11 per group) which among two groups of them were pre-treated with 3 mg/kg IBNtxA
before getting post-injection with 10 mg/kg morphine and another group with saline. Other
two groups were pretreated with DMSO prior to receive morphine 10 mg/kg or saline.
Among them animals, received IBNtxA and Morphine traveled significantly less distance
than the animals which received DMSO vehicle before getting the same dose of morphine
which indicated IBNtxA can suppress morphine-induced hyperlocomotion. Data are
presented as means ± SEM.

59

Figure 18. Drug discrimination study with morphine-trained animals. CD-1 outbred mice
(n=8) were trained for almost 60 sessions and the duration of each session was an hour and
10±5 mins. The well-trained animals with more than 80% correct response, were tested for
discrimination among vehicle, morphine (0.3, 1, 3, and 10 mg/kg) and novel drug IBNtxA
3 mg/kg, the result showed that IBNtxA was a partial substitution of morphine. Pretreatment (i.p.) with naloxone 1 mg/kg prior to injecting morphine, showed that the
morphine response is as lower as a percent of vehicle training responses to morphine side.
This is obvious that antagonist naloxone blocked the morphine. The percent of morphine
responding was calculated by taking the ratio of morphine responses over total responses.
Data presented as means ± SEM.
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Figure 1913: Rate effects of drug doses in the drug discrimination study with morphinetrained animals. CD-1 outbred mice (n=8) were trained for almost 60 sessions and the
duration of each session was an hour and 10±5 mins. The well-trained animals with more
than 80% correct response, were tested for discrimination among vehicle, morphine (0.3,
1, 3, and 10 mg/kg) and novel drug IBNtxA 3 mg/kg, the result showed that IBNtxA was
a partial substitution of morphine. The rate of responding was calculated as:
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑒 =

𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑡𝑖𝑚𝑒 (𝑚𝑎𝑥𝑖𝑚𝑢𝑚 60 𝑚𝑖𝑛𝑠)

Data presented as means ± SEM.
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Chapter 3
Mycobacterium vaccae Immunization for Drug Addiction, Relapse, and Withdrawal
Background
Addiction is a major health issue which brings upon other health complications with
economic burdens. According to the 2016 National Survey on Drug Use and Health, around
1.7 million people misused stimulant drugs in the U.S.A. and 2.2 percent of them are young
adults.(Center, 2011) In this survey, it has been reported that almost 1.9 million people
were current cocaine users. Psychostimulants promote dopamine pathways by signaling in
the nucleus accumbens, the reward producing area, which calls upon euphoria feelings that
eventuate the drug-taking and -seeking and leads to addiction. (Nestler, 2005) Furthermore,
long-time cocaine exposure causes neuroinflammation which is another underlying reason
for cocaine addiction. The consequences of physiological disorders because of cocaine use
are—physical withdrawal, increasing use with time, and failure to participate in works at
work, school, or home.
Unfortunately, there is no current FDA-approved treatment for addiction to
psychostimulant substances and finding any medicine to prevent addiction and relapse is
preeminent for America as well as the rest of the world.
Mycobacterium vaccae
The aims of our collaborative research were in finding new medicine for drug
treating addiction, relapse, and withdrawal. Our research was designed based on some
unique neuropharmacological properties of M. vaccae which is a nonpathogenic
environmental bacterium, belongs to the family of Mycobacteriaceae that is found in the
soil. Multiple studies have proved that M. vaccae has positive effects on certain
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neurological disorders such as post-traumatic stress. Immunization with heat-killed M.
vaccae has immunoregulatory properties and can prevent stress-induced spontaneous
colitis, over neuroinflammation, also it has both anxiolytic or fear-reducing effects. (Reber
et al., 2016) It works by stimulating the neurons which contain serotonin signaling
pathways and heightens the serotonin levels in the dorsal raphe nucleus to respond to stress
and anxiety-like behavioral. (Lowry et al., 2007)
Based on M. vaccine's pharmacological profile—it might have effects against
cocaine addiction and relapse and we studied the effect of M. vaccae immunization on
cocaine-induced CPP and stress-induced reinstatement of cocaine CPP.
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Figure 140. (Bristol, 2007) Colonies of Mycobacterium vaccae which was Sauton's agar.
(Bristol, 2007) This bacterium is usually found in soil, which is not harmful to human; was
isolated in Uganda and that it showed immunization effect against leprosy. After that
numerous studies indicated its medical value as a vaccine for different diseases. (Wallis &
Johnson, 2009)
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Methodology
Animal and drug. Drug and Animal: C57 BL/6 male mice were used for this
investigation and as drugs cocaine 30 mg/kg, heat-killed M. vaccae (0.1 mg, s.c.) or vehicle
(borate-buffered saline) were administrated according to the research plan. M. vaccae (3 x
0.1 mg, s.c.), regimen is reliable in both mice and rat models for neurological and
behavioral studies.
General cocaine CPP procedure. The CPP training for cocaine is almost the same
as mentioned in the early in methodology session. But prior to providing cocaine CPP
training, two groups of animals—one group was preimmunized M. vaccae (3 x 0.1 mg,
s.c.) and another group was preimmunized with vehicle (s.c. borate-buffered saline). To
confirm the proper preimmunization, each animal had an individual animal ID to identify
the animal which received the vehicle and M. vaccae. The immunization was occurred
inside the CMRSU vivarium three times over 14 days with even time intervals.
When immunization was done then the cocaine CPP procedure was started which
also followed an unbiased procedure where any animal showing >70% initial preference
for any compartment was excluded before further training and the duration of training or
test session was also for 30 minutes. The qualified animals were then trained over 10 days,
either after getting cocaine or saline vehicle injections (i.p.). After 10 days of consecutive
training, animals were tested for CPP expression to know the preference score for cocainepaired side and whether preimmunization did affect the cocaine-induced CPP or not.
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Figure 151. The schematic presentation of M. Vaccace preimmunization test for cocaine
CPP methodology. The animals arrive in vivarium of Cooper Medical School of Rowan
University (CMSRU) where theyhave been kept for five days. Prior to inject (s.c.) M.
vaccae (3 x 0.1 mg) or vehicle (borate-buffered saline) three times in 14 days, they were
handled for two days to make them comfortable with researchers. After immunization,
they are being placed in CPP chambers for initial bias test for three sessions and after that
ten days (ten sessions) CPP training. After successfully completing training, they have been
tested for CPP expression and finally stress-induced (forced swim ) reinstatement test
followed by CPP extinction.
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Then after two sessions of extinction, we tested the for stress-induced cocaine
reinstatement. We used the forced swim method to induce stress prior to placement in CPP
chamber which has been detailed earlier.
Statistical Analysis.
During CPP expression
𝑃𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑆𝑐𝑜𝑟𝑒
= time spent in drug side on test day
− time spent in drug side before training
During reinstatement test
Preference Score = time spent on drug side − time spent in the vehicle side

Result: M. vaccae attenuated stress-induced cocaine CPP
Our investigation found that the animals which were preimmunized with heat-killed
M. vaccae did not affect the 30 mg/kg cocaine-induced CPP immediately after training and
it was near same as vehicle immunized animals. But the in stress-induced reinstatement,
there was significant changed between the vehicle and M. vaccae group. Heat-killed M.
vaccae preimmunized animals showed almost no preference for the cocaine-paired side but
the animals which preimmunized with vehicle scored higher.This of result indicated that
though M. vaccae did not affect the cocaine-induced CPP after training it effectively
attenuated the stress-induced cocaine CPP.
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Discussion
Relapse is the most unavoidable event during the addiction treatment one of the
principal reasons for relapse is stress. (Sinha, Garcia, Paliwal, Kreek, & Rounsaville, 2006)
Scientists often test this human stress-induced relapse in animals through stress-induced
reinstatement. (Y. Shaham, U. Shalev, L. Lu, H. de Wit, & J. Stewart, 2003) Like any other
addiction treatment, cocaine relapse is also challenging to fight. Heat-killed M. vaccae
preimmunization clearly reduced the effects of stress-induced relapse for cocaine addictive
animals ( Figure 22). Since M. vaccae also has anxiolytic effects, and our investigation
proved the anti-relapse effects, it might be beneficial for the patients who are in treatment
for cocaine addiction.

Conclusion
Finding a new medicine for treating cocaine addiction is intriguing but at the same
time one of demanding job. Our current umbrella project for finding a medicine for
neuropsychiatric disorders including addiction, abuse and dependence is continuing
investigation with new idea and with new collaborations. Investigations on properties of
M. vaccae are happeining now with some specific set of goals which will soon decode
more addiction neuropharamclogical properties of this nonpathogen bacterium along with
the postive effects on stress-induced reinstatement for cocaine.
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Figure 162. M. vaccae preimmunization effects on cocaine CPP. Two groups of animals
(n=8-12 for each group) were used for this test. Animals were pre-immunized with vehicle
or heat-killed M. vaccae three times in seven days intervals and then were palced for three
initial preference test , 10 sessions of CPP training with cocaine 30 mg/kg. After training
animals were tested for CPP expression and then, stress-induced (forced-swim)
reinstatement followed by extinctions. Animals nevertheless immunization with M.
vaccae or vehicle, did not alter cocaine 30 mg/kg induced CPP acquisition wherein both
vehicle and heat-killed M. vaccae (3 x 0.1 mg, s.c.) showed the considerable score for the
cocaine-paired side. But after the extinction sessions, stress-induced (forced-swim)
reinstatement was attenuated by heat-killed M. vaccae preimmunization. Data presented as
means ± SEM. *p < 0.05, repeated-measures 2-way ANOVA with Sidak's multiple
comparisons test.
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